CYP2C19
Selected indexed studies
- CYP2C19 genotype-phenotype correlation: current insights and unanswered questions. (Drug Metab Pers Ther, 2024) [PMID:39663234]
- The CYP2C19 enzyme polymorphism. (Pharmacology, 2000) [PMID:10971203]
- Impact of CYP2C19 gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. (Pharmacogenomics, 2022) [PMID:36222113]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- CYP2C19 genotype-phenotype correlation: current insights and unanswered questions. (2024) pubmed
- The CYP2C19 enzyme polymorphism. (2000) pubmed
- Impact of CYP2C19 gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. (2022) pubmed
- CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs. (2018) pubmed
- CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. (2001) pubmed
- Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review. (2025) pubmed
- CYP2C19 Genotyping to Guide Antiplatelet Therapy for the Secondary Prevention of Lacunar Strokes. (2023) pubmed
- Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives. (2022) pubmed
- CYP2C19*2 polymorphism and clopidogrel resistance. (2020) pubmed
- Another Step Toward CYP2C19 Genotype-Guided Therapy in Treatment With Dual Antiplatelet Therapy. (2023) pubmed